What's Hot
View all perspectives
Eric Dein
1 year ago
A#2316 #ACR23 @RheumNow
91 SLE pts w COVID v 182 SLE wo COVID ifn
11 SLE/COVID: serious disease
1 death, 7 severe compl
W/in 90d, 15% mild/mod SLE flare 2% severe SLE flare
Flare rate 17.6% higher than no COVID ifn 5% p=0.001
High HV ifn (2% v 1%)
dsDNA/C3 changes not signif diff https://t.co/dxGJNNWuFy
Bella Mehta bella_mehta
1 year ago
How do we treat #VEXAS - UBA1 mutation
Large multicenter cohort - 110 pts, 99% M
Confirms the benefit of JAKi and tocilizumab
Others not so much
@RheumNow #ACR23 #ACRBest
#abstL03 https://t.co/tRjO31IHiD
Mike Putman EBRheum
1 year ago
Speaking of real RA drugs for RA-ILD... large multicenter study finds 4 in 5 patients who received ABA had lung stabilization
Nice to see observational data; this would be an amazing opportunity for a pragmatic open label RCT
@RheumNow #ACR23 Abstr 2165 https://t.co/LTpfjTVAur
sheila
1 year ago
Retrospective database study from Japan of PsA pts:
At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx.
Dc rates lowest for risankizumab
🤔Reasons for switching/discontinuation not mentioned.
#ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE
Eric Dein
1 year ago
A#2313 #ACR23 @RheumNow
Utilization of inpt palliative care incr from 2016-2020 in SLE admits from 1.8% 2016 to 2.6% 2020
Pall care use incr: older pt, comorbid index, teaching, large hosps
Lower use: age <35 yo, Black & Hispanic race
Need to address racial disparities in utiliz https://t.co/wQ8NOhm9lK https://t.co/3tJgt4MMDf
Bella Mehta bella_mehta
1 year ago
Extended-Release Fluticasone Propionate for Injectable Suspension - EP-104IAR
Phase 2 Randomized (1:1), Double-blind, Vehicle-Controlled Trial
318 pts, 57% F, age 64,
Clinically and statistically significant pain relief for 14 weeks compared to vehicle
@RheumNow #ACR23 #abstL04
Mike Putman EBRheum
1 year ago
Important data re:ADVOCATE study and health related quality of life
Interesting question: is this due to AVA or just simply giving less steroids?
I discuss this on recent podcast: https://t.co/7Jm6ArFpsB
@RheumNow #ACR23 https://t.co/53T1p2Vvyb
Eric Dein
1 year ago
@EricFMorand SPOCS Study: A#2263 @ACR23
826 pts - 71% high IFN gene sig
Mean SLEDAI-2K lower with low IFNGS
6mo: pts reports 1+ flare 19% high IFNGS, 16% low. Both grps 6.7% LLDAS, but remission 4% low/1.7% high
In 36 mo, <10% LLDAS, <10% remission
@earlyARA @RheumNow https://t.co/z5v4TBVuDG
sheila
1 year ago
Post hoc analysis of Ph2 AURA-LV & Ph3 AURORA1
⬆️VOC-treated pts achieved CRR at 1yr vs. control arm (41.0% vs. 21.9%; OR 2.48, p< 0.0001) and PRR at 1yr (OR 2.3, p< 0.0001)
Similar safety profiles
VOC: Additional tx option for LN pts w/ UPCR >/=2g/g
#ACR23 ABST2326 @RheumNow https://t.co/9z1n3s7umU
Mike Putman EBRheum
1 year ago
Very cool meta analysis of IL17i RCTs in PsA
No change in MACE in DMARD naieve pts initiating IL17i across RCTs
A skosh underpowered but worthwhile question & useful data
@RheumNow #ACR23 Abstr2254 https://t.co/ZN8QYgSA1A
Eric Dein
1 year ago
A#2297 #ACR23 @RheumNow
Baseline IFNα predicts complete response at 2 yrs in LN
HIgh IFNα: incr risk of 2+ renal flare
Increase of 1 unit of IFNα incr risk of 2+ flares by 35% & risk of decr GFR
IFNα cutoff 0.6 for 2+ flare, 1.3 for progr to eGFR <15
AUC 0.6 (weak predictor) https://t.co/FKeDJVNyYj
sheila
1 year ago
In this older grp of pts w/ chronic LBP, significant overlaps of deg & inflamm features on spinal imaging of DC, DISH & axSpA pts were seen
Also, +comorbids: HTN in DC; DM in DISH; smoking in axSpA
THM? DC & DISH are also axSpA mimics
#ACR23 ABST1862 @Rheumnow @rheumarhyme https://t.co/uNIwRchF1g
Eric Dein
1 year ago
HCQ improves complements
A#2327 #ACR23 @RheumNow
Petri @jhrheumatology @andreafava
Pts w/ low complement & low HCQ levels
In pts who increased HCQ WB level >50 ng/mL, incr in mean C3 (p=0.02) v HCQ that did not incr
More nml C4 levels (p=.003) and incr mean C4 (p=.004) on HCQ https://t.co/J7PIuaRTO8
Eric Dein
1 year ago
HCQ Discontinuation
A#2343 #ACR23 @RheumNow
42 pts d/c HCQ
19% flared in past yr before d/c
D/c reasons: retina tox 57%, self-dc 17%, other eye issue 12%
26% flare in yr after d/c - strongest ass for flare: mean C3, dsDNA+ at index visit https://t.co/d4TqneS46u
Mike Putman EBRheum
1 year ago
Another day, another bimekizumab (IL17i) study
Across 2 trials, improved PsA specific QOL ("PsAID") metrics
Nice to see focus on PROs & I always love a good spidergram
@RheumNow #ACR23 Absr2249 https://t.co/dsLXstPzt2
Poster Hall